Analyst Research

Report Title Price
Provider: Sadif Analytics Prime
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aerocrine AB Announces Positive Trial Results of FeNO-guided Anti-inflammatory Treatment


Friday, 11 Oct 2013 04:09am EDT 

Aerocrine AB announced that a new randomised clinical trial shows lower incidence of asthma exacerbations and increased asthma control with he Company's Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment. 

Related Company News

Company Quote

4.5
0.03 +0.67%
11:29am EDT